Commentary

Apple’s ResearchKit

Publish date: March 17, 2015

 

Dr. Benabio is a partner physician in the department of dermatology of the Southern California Permanente Group in San Diego, and volunteer clinical assistant professor at the University of California, San Diego. Dr. Benabio is @dermdoc on Twitter.

Pages

Recommended Reading

More cancer patients surviving longer, but age-based disparities remain
MDedge Hematology and Oncology
Trastuzumab emtansine investigated for early-stage breast cancer
MDedge Hematology and Oncology
21-gene recurrence score assay underwent rapid uptake in U.S. breast cancer patients
MDedge Hematology and Oncology
SEER: Breast cancer survivors at increased risk of thyroid cancer
MDedge Hematology and Oncology
VIDEO: Following breast cancer diagnosis, risk of thyroid cancer rises
MDedge Hematology and Oncology
Lapatinib inferior to trastuzumab for HER2-positive breast cancer
MDedge Hematology and Oncology
Precision medicine in the making
MDedge Hematology and Oncology
Palbociclib and letrozole for ER-positive, HER2-negative advanced breast cancer
MDedge Hematology and Oncology
Effect of ArginMax on sexual functioning and quality of life among female cancer survivors: results of the WFU CCOP Research Base Protocol 97106
MDedge Hematology and Oncology
The need for decision and communication aids: a survey of breast cancer survivors
MDedge Hematology and Oncology